• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evercore ISI initiated coverage on Summit Therapeutics with a new price target

    3/12/25 7:33:36 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    Evercore ISI initiated coverage of Summit Therapeutics with a rating of Outperform and set a new price target of $30.00
    Get the next $SMMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Underperform
    Leerink Partners
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    3/21/2025Overweight
    Cantor Fitzgerald
    3/12/2025$30.00Outperform
    Evercore ISI
    2/28/2025$42.00Buy
    Goldman
    1/8/2025$35.00Buy
    Truist
    12/11/2024$30.00Overweight
    Wells Fargo
    12/6/2024$31.00Buy
    Jefferies
    More analyst ratings

    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Co-Chief Executive Officer Zanganeh Mahkam exercised 74,545 shares at a strike of $2.64 (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      6/2/25 5:01:16 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Co-Chief Executive Officer Duggan Robert W exercised 74,545 shares at a strike of $2.64, increasing direct ownership by 0.01% to 555,754,696 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      6/2/25 4:55:56 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:17:22 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    SEC Filings

    See more
    • Summit Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      6/20/25 5:07:50 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      6/17/25 4:13:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      5/30/25 4:17:49 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care